A new study has found that CRISPR gene-editing therapy can reduce high cholesterol levels. The treatment, which was tested in a small, first-in-human trial, was reported to safely lower cholesterol and triglycerides, with some outlets citing significant reductions in bad cholesterol levels. The extent of the reduction varies across reports, but the therapy is described as a potential "one and done" treatment that could help prevent heart disease.